title: Single intravitreal injection of triamcinolone combined with bevacizumab for the treatment of diffuse diabetic macular oedema refractory to grid photocoagulation.
authors.forename: Marco S
authors.initials: MS
authors.lastname: Folgosa
authors.forename: André
authors.initials: A
authors.lastname: Messias
authors.forename: Clécio
authors.initials: C
authors.lastname: Takata
authors.forename: Rogério A
authors.initials: RA
authors.lastname: Costa
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Jorge
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D056965:Injections, Intraocular; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D005938:Glucocorticoids; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide